Compare TRUP & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | QURE |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.7M | 1.1B |
| IPO Year | 2014 | 2013 |
| Metric | TRUP | QURE |
|---|---|---|
| Price | $21.88 | $26.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $45.80 | $45.00 |
| AVG Volume (30 Days) | 351.5K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 295.65 | 29.67 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,439,305,000.00 | $13,107,000.00 |
| Revenue This Year | $11.79 | $126.12 |
| Revenue Next Year | $8.83 | $200.43 |
| P/E Ratio | $200.00 | ★ N/A |
| Revenue Growth | ★ 11.95 | N/A |
| 52 Week Low | $21.16 | $8.73 |
| 52 Week High | $57.35 | $71.50 |
| Indicator | TRUP | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 55.52 |
| Support Level | $21.16 | $23.06 |
| Resistance Level | $29.24 | $29.03 |
| Average True Range (ATR) | 0.94 | 1.84 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 34.80 | 38.29 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.